Table 1

Baseline characteristics of 1365 persons with DM included in the registry

TotalT1DMT2DMOther forms of DM
Number (%)1365 (100)1054 (77.2)223 (16.3)88 (6.5)
 Age, years46.1 (16.1)42.8 (15.5)59.9 (10.8)52.6 (11.6)
 Male gender, n (%)744 (54.5)555 (52.7)142 (63.7)30 (48.4)
 Therapy
 Insulin monotherapy1131 (82.9)100 (100.0)88 (39.5)45 (72.6)
 Insulin and OBGLD234 (17.1)63 (5.9)130 (5.8)17 (19.3)
Presence of microvascular complications
 Neuropathy, n (%)230 (16.8)154 (14.6)23 (10.3)6 (9.7)
 Albuminuria, n (%)244 (17.9)180 (17.1)50 (22.4)10 (16.1)
 Retinopathy, n (%)247 (18.1)199 (18.9)39 (17.5)6 (9.7)
Presence of cardiovascular disease
 Angina pectoris, n (%)33 (2.4)15 (1.4)14 (6.3)2 (3.2)
 PCI, n (%)52 (3.8)31 (2.9)14 (6.3)4 (6.5)
 Myocardial infarction, n (%)40 (2.9)23 (2.2)14 (6.3)2 (3.2)
 CABG, n (%)37 (2.7)23 (2.2)11 (4.9)2 (3.2)
 TIA, n (%)28 (2.1)14 (1.3)9 (4.0)3 (4.8)
 CVA, n (%)23 (1.7)14 (1.3)6 (2.7)3 (4.8)
 Peripheral arterial disease, n (%)51 (3.7)29 (2.8)18 (8.1)2 (3.2)
Indication for FSL-FGM use
 Hypoglycemia unawareness 1156 (11.4)119 (11.3)25 (11.2)8 (12.9)
 Unexpected hypoglycemias 2410 (30.0)322 (30.6)56 (25.1)25 (40.3)
 HbA1c>70 mmol/mol (8.5%) 3294 (21.5)202 (19.2)80 (35.9)6 (9.7)
 Unwanted sensation loss of the fingers 419 (1.4)14 (1.3)5 (2.2)0 (0.0)
 Occupational hazards with hypoglycemia 557 (4.2)39 (3.7)11 (4.9)4 (6.5)
 Individuals eligible for CGM 645 (3.3)40 (3.8)2 (0.9)2 (3.2)
 Individuals already using FSL-FGM 7100 (7.3)76 (7.2)14 (6.3)6 (9.7)
 Multiple indications284 (20.8)242 (23.0)30 (13.5)11 (17.7)
  • Data are presented as numbers (%), means (SD) or medians (25th, 75th centiles).

  • CABG, coronary artery bypass grafting;CGM, continuous glucose monitoring; CVA, cerebral vascular event; DM, diabetes mellitus; FSL-FGM, FreeStyle Libre flash glucose monitoring; OBGLD, oral blood glucose lowering drugs;PCI, percutaneous coronary intervention; T1DM, type I diabetes mellitus; T2DM, type II diabetes mellitus; TIA, transient ischemic attack.